Michael Cope, MD
Obstetrics & Gynecology · Little Rock, ARNPI 1588639959
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $140,668 of the $146,891 with a category attached, or 95.8%. Organon accounts for 81.4% of it on its own, with 32 other manufacturers making up the rest. Among obstetrics & gynecology clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 364 payments — averaging $403.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$119K
- Merck$24K
- AbbVie$407
- Astellas Pharma US Inc$389
- Bayer$311
- Pfizer$296
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$140,66896%
- Travel & lodging$2,1461%
- Food & beverage$3,8723%
- Education$2060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 172 | $119,498 |
| Merck | 39 | $24,354 |
| AbbVie(2 entities) | 26 | $407 |
| Astellas Pharma US Inc | 12 | $389 |
| Bayer | 17 | $311 |
| Pfizer | 21 | $296 |
| Minerva Surgical, Inc | 6 | $208 |
| Therapeuticsmd, Inc. | 4 | $162 |
| Sumitomo Pharma America, Inc. | 9 | $143 |
| Mayne Pharma Commercial LLC | 9 | $134 |
| Biogen | 5 | $116 |
| Exeltis, USA Inc. | 5 | $109 |
| Intuitive Surgical | 1 | $101 |
| Avion Pharmaceuticals | 5 | $83 |
| Evofem Biosciences, Inc. | 5 | $79 |
| Myriad Women's Health, Inc. | 1 | $65 |
| Hologic Sales And Service, LLC | 4 | $58 |
| Gynesonics, Inc. | 1 | $47 |
| Shield Therapeutics Inc | 2 | $46 |
| Mylan Pharmaceuticals Inc. | 3 | $42 |
| AMAG Pharmaceuticals, Inc. | 2 | $31 |
| Myovant Sciences Inc. | 2 | $30 |
| Lupin Inc. | 2 | $28 |
| Coloplast | 2 | $27 |
| AstraZeneca | 1 | $17 |
| Scynexis, Inc. | 1 | $17 |
| Conmed Corporation | 1 | $17 |
| Agile Therapeutics, Inc. | 1 | $15 |
| Duchesnay USA Incorporated | 1 | $15 |
| Urovant Sciences Inc | 1 | $15 |
| Pharmacosmos Therapeutics Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Kinex Medical Company LLC | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXPLANON$128,782
- BIJUVA$114
- Da Vinci Surgical System$101
How this compares
$146,891 in reported general payments places this provider in the 95th percentile of 272 obstetrics & gynecology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VeozahFezolinetant | 24 | $13,274 |
| MyrbetriqMirabegron | 19 | $12,679 |
| Estradiol | 180 | $7,155 |
| PremarinEstrogens, Conjugated | 12 | $3,450 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 34 | $2,248 |
| Estradiol (Twice Weekly)Estradiol | 19 | $1,910 |
| Tolterodine Tartrate ErTolterodine Tartrate | 16 | $1,004 |
| ProgesteroneProgesterone, Micronized | 27 | $954 |
| Oxybutynin Chloride ErOxybutynin Chloride | 35 | $537 |
| Oxazepam | 12 | $376 |
| ValacyclovirValacyclovir Hcl | 16 | $363 |
| Zolpidem Tartrate | 35 | $52 |
| Lorazepam | 20 | $48 |
| Alprazolam | 11 | $18 |
| Diazepam | 13 | $17 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncVeozah, Myrbetriq | $389 | $25,95343 claims |
| PfizerPremarin | $296 | $3,45012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 272 obstetrics & gynecology providers in Arkansas.
Other obstetrics & gynecology in Little Rock
- David ShenkerLittle Rock$28K
- Julia GoodwinLittle Rock$16K
- Ananth RanganathanLittle Rock$11K
- Mary RacherLittle Rock$11K
- Nirvana ManningLittle Rock$10K
- Sharai AmayaLittle Rock$9K
- Emily WilliamsLittle Rock$9K
- Shelly GibbsLittle Rock$8K
- Stacy Ulmer-PinterLittle Rock$8K
- Leticia JonesLittle Rock$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.